Nectar Lifesciences Balance Sheet Health
Financial Health criteria checks 4/6
Nectar Lifesciences has a total shareholder equity of ₹10.7B and total debt of ₹6.4B, which brings its debt-to-equity ratio to 59.4%. Its total assets and total liabilities are ₹21.9B and ₹11.2B respectively. Nectar Lifesciences's EBIT is ₹969.8M making its interest coverage ratio 1.2. It has cash and short-term investments of ₹203.0M.
Key information
59.4%
Debt to equity ratio
₹6.36b
Debt
| Interest coverage ratio | 1.2x |
| Cash | ₹203.01m |
| Equity | ₹10.69b |
| Total liabilities | ₹11.22b |
| Total assets | ₹21.91b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: NECLF's short term assets (₹12.8B) exceed its short term liabilities (₹9.7B).
Long Term Liabilities: NECLF's short term assets (₹12.8B) exceed its long term liabilities (₹1.5B).
Debt to Equity History and Analysis
Debt Level: NECLF's net debt to equity ratio (57.5%) is considered high.
Reducing Debt: NECLF's debt to equity ratio has reduced from 82.8% to 59.4% over the past 5 years.
Debt Coverage: NECLF's debt is well covered by operating cash flow (35.4%).
Interest Coverage: NECLF's interest payments on its debt are not well covered by EBIT (1.2x coverage).